| Question 1: 1. Which of the following is NOT a core service of IROC: |
| Reference: | FitzGerald TJ. A new model for imaging and radiation therapy quality assurance in the National Clinical Trials Network of the National Cancer Institute. Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):272-3. |
| Choice A: | Site qualification |
| Choice B: | Credentialing |
| Choice C: | Protocol Development |
| Choice D: | Car Washing |
| Choice E: | Case Review |
| Choice F: | Data Management |
| Question 2: 2. The purpose of IROC’s end-to-end RT credentialing phantoms are to: |
| Reference: | Molineu A, Followill DS, Balter PA, Hanson WF, Gillin MT, Huq MS, Eisbruch A, Ibbott GS. Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):577-83. |
| Choice A: | Verify that plan quality matches the protocol requirements |
| Choice B: | Verify that contouring processes are consistent with protocol requirements |
| Choice C: | Verify that the intended and delivered dose agree |
| Choice D: | Verify that protocol-specific dose constraints are used |
| Question 3: The standardization of structure names is a critical component of making shared data more accessible and usable to benefit patient care. |
| Reference: | AAPM Task Group Report 263 |
| Choice A: | True |
| Choice B: | False |
| Question 4: Individualized dosimetry treatment planning is not necessary for radiopharmaceutical therapy. |
| Reference: | Garin et al. Lancet Gastroenterol Hepatol 2021 |
| Choice A: | True |
| Choice B: | False |
| Question 5: What is TRIAD used for? |
| Reference: | Bibb Allen, David C. Levin, Michael Brant-Zawadzki, Frank James Lexa, Richard Duszak, ACR White Paper: Strategies for Radiologists in the Era of Health Care Reform and Accountable Care Organizations: A Report From the ACR Future Trends Committee, Journal of the American College of Radiology, Volume 8, Issue 5, 2011, Pages 309-317 |
| Choice A: | Spearfishing |
| Choice B: | Study image submission and site accreditation |
| Choice C: | Site qualification and study image submission |
| Choice D: | Site qualification and site accreditation |
| Question 6: What of the following are not among the benefits of blinded, independent central review (BICR) in cancer trials? |
| Reference: | Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., & Mooney, M. M. (2008). Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(22), 3791–3796. |
| Choice A: | Gives radiologists valuable exposure to cancer images |
| Choice B: | Help achieve unbiased results by minimizing differences in subjective imaging endpoint evaluation across sites and readers in a multicenter study |
| Choice C: | Better discern the reliability of marginal results, particularly from local reads |
| Choice D: | Minimize bias in evaluation of progression introduced by knowledge of treatment arm assignment |
